Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CE Stock Summary
Top 10 Correlated ETFs
CE
In the News

The 7 Most Undervalued Warren Buffett Stocks to Buy in September 2023
If you're among the millions of investors concerned about where to put your money to work, undervalued Warren Buffett stocks to buy may be the place to focus on. Specifically, by aligning your portfolio with certain compelling individual holdings of Berkshire Hathaway (NYSE: BRK-B ), you might be able to get a leg up on market vagaries.

The 3 Most Undervalued Materials Stocks to Buy in September 2023
My mission, should I choose to accept it, is to find the three most undervalued materials stocks to buy in September. Dr. Ed Yardeni and his capable crew at Yardeni Research produce interesting charts weekly about the S&P 500.

Celanese (CE) Inks Deal With Population Council for VitalDose
The VitalDose platform by Celanese (CE) Delivery Platform has a long history of application in approved parenteral drug options.

Celanese (CE) Up 0.8% Since Last Earnings Report: Can It Continue?
Celanese (CE) reported earnings 30 days ago. What's next for the stock?

Warren Buffett Just Sold These 3 Stocks. You Should Too.
Warren Buffet is arguably the most successful investor of all time. And while he is known as both a value investor and a long-term, buy-and-hold market participant, he's not averse to selling a stock if it runs against him or the reasons why he bought shares in the first place turn out to be incorrect.

Celanese (CE) Refinances Debt to Extend Maturity & Reduce Costs
Celanese (CE) is refinancing its debt to extend the maturity of its debt and reduce its borrowing costs by 14 basis points.

Warren Buffett's Berkshire Hathaway bet on 3 homebuilders - and sold and slashed a bunch of stocks last quarter
Warren Buffett's Berkshire Hathaway added a trio of homebuilders to its portfolio last quarter. The investor's company exited three stocks and slashed several of its positions, SEC filings show.

Celanese (CE) Q2 Earnings and Sales Fall Short of Estimates
Celanese (CE) misses second-quarter earnings and sales estimates due to slow demand recovery and production cuts.

Celanese (CE) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Celanese (CE) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Celanese (CE) Q2 Earnings and Revenues Miss Estimates
Celanese (CE) came out with quarterly earnings of $2.17 per share, missing the Zacks Consensus Estimate of $2.46 per share. This compares to earnings of $4.99 per share a year ago.
CE Financial details
CE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 53.28 | 50.82 | 48.01 | 76.76 | 89.25 | |
Net income per share | 8.99 | 6.88 | 16.85 | 16.99 | 17.48 | |
Operating cash flow per share | 11.6 | 11.74 | 7.22 | 15.8 | 16.78 | |
Free cash flow per share | 9.09 | 8.75 | 4.13 | 11.6 | 11.77 | |
Cash per share | 3.5 | 4.06 | 12.63 | 4.91 | 13.91 | |
Book value per share | 22.22 | 20.23 | 29.93 | 37.66 | 52.01 | |
Tangible book value per share | 14.98 | 12.2 | 20.46 | 21.49 | -47.44 | |
Share holders equity per share | 22.22 | 20.23 | 29.93 | 37.66 | 52.01 | |
Interest debt per share | 27.22 | 33.91 | 34.3 | 38.28 | 142.54 | |
Market cap | 12.08B | 15.25B | 15.31B | 18.69B | 11.08B | |
Enterprise value | 15.17B | 18.88B | 18.28B | 22.32B | 24.62B | |
P/E ratio | 10.01 | 17.9 | 7.71 | 9.89 | 5.85 | |
Price to sales ratio | 1.69 | 2.42 | 2.71 | 2.19 | 1.15 | |
POCF ratio | 7.76 | 10.49 | 18.01 | 10.64 | 6.09 | |
PFCF ratio | 9.9 | 14.07 | 31.5 | 14.49 | 8.68 | |
P/B Ratio | 4.05 | 6.08 | 4.34 | 4.46 | 1.97 | |
PTB ratio | 4.05 | 6.08 | 4.34 | 4.46 | 1.97 | |
EV to sales | 2.12 | 3 | 3.23 | 2.61 | 2.54 | |
Enterprise value over EBITDA | 9.81 | 18.71 | 21.26 | 10.09 | 14.06 | |
EV to operating cash flow | 9.74 | 12.98 | 21.51 | 12.71 | 13.53 | |
EV to free cash flow | 12.43 | 17.41 | 37.62 | 17.3 | 19.29 | |
Earnings yield | 0.1 | 0.06 | 0.13 | 0.1 | 0.17 | |
Free cash flow yield | 0.1 | 0.07 | 0.03 | 0.07 | 0.12 | |
Debt to equity | 1.18 | 1.63 | 1.11 | 0.99 | 2.67 | |
Debt to assets | 0.38 | 0.43 | 0.36 | 0.35 | 0.57 | |
Net debt to EBITDA | 2 | 3.59 | 3.46 | 1.64 | 7.73 | |
Current ratio | 1.62 | 1.58 | 1.91 | 1.52 | 1.63 | |
Interest coverage | 10.67 | 7.25 | 6.09 | 21.38 | 3.4 | |
Income quality | 1.28 | 1.69 | 0.43 | 0.93 | 0.96 | |
Dividend Yield | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | |
Payout ratio | 0.23 | 0.35 | 0.15 | 0.16 | 0.16 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Intangibles to total assets | 0.15 | 0.15 | 0.14 | 0.18 | 0.43 | |
Capex to operating cash flow | -0.22 | -0.25 | -0.43 | -0.27 | -0.3 | |
Capex to revenue | -0.05 | -0.06 | -0.06 | -0.05 | -0.06 | |
Capex to depreciation | -0.97 | -1.04 | -1.02 | -1.24 | -1.14 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0 | 0.01 | 0.01 | |
Graham number | 67.03 | 55.95 | 106.53 | 120 | 143.01 | |
ROIC | 0.17 | 0.11 | 0.08 | 0.19 | 0.09 | |
Return on tangible assets | 0.15 | 0.11 | 0.21 | 0.19 | 0.13 | |
Graham Net | -29.43 | -37.69 | -34.85 | -43.87 | -144.99 | |
Working capital | 1.1B | 1.01B | 1.79B | 1.3B | 2.54B | |
Tangible asset value | 2.01B | 1.51B | 2.41B | 2.39B | -5.14B | |
Net current asset value | -3.06B | -3.81B | -3.25B | -3.63B | -13.56B | |
Invested capital | 1.18 | 1.63 | 1.11 | 0.99 | 2.67 | |
Average receivables | 1.27B | 1.25B | 1.21B | 1.45B | 1.86B | |
Average payables | 813M | 799.5M | 788.5M | 978.5M | 1.34B | |
Average inventory | 973M | 1.04B | 1.01B | 1.25B | 2.17B | |
Days sales outstanding | 67.24 | 68.46 | 80.16 | 71.27 | 77.51 | |
Days payables outstanding | 57.68 | 60.69 | 66.69 | 72.31 | 75.97 | |
Days of inventory on hand | 73.66 | 80.77 | 81.84 | 95.01 | 140.53 | |
Receivables turnover | 5.43 | 5.33 | 4.55 | 5.12 | 4.71 | |
Payables turnover | 6.33 | 6.01 | 5.47 | 5.05 | 4.8 | |
Inventory turnover | 4.96 | 4.52 | 4.46 | 3.84 | 2.6 | |
ROE | 0.4 | 0.34 | 0.56 | 0.45 | 0.34 | |
Capex per share | -2.51 | -2.99 | -3.09 | -4.2 | -5.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 22.94 | 21.22 | 21.64 | 26.26 | 25.67 | |
Net income per share | 4 | 1.76 | 7.07 | 0.84 | 2.02 | |
Operating cash flow per share | 4.57 | 4.31 | 4.99 | -0.88 | 7 | |
Free cash flow per share | 3.42 | 3.03 | 3.67 | -2.39 | 5.67 | |
Cash per share | 7.29 | 89.19 | 13.9 | 10.74 | 11.9 | |
Book value per share | 45.02 | 45.65 | 51.95 | 52.11 | 51.64 | |
Tangible book value per share | 29.54 | 30.94 | -47.39 | -46.9 | -45.75 | |
Share holders equity per share | 45.02 | 45.65 | 51.95 | 52.11 | 51.64 | |
Interest debt per share | 37.82 | 117.09 | 140.19 | 141.05 | 137.05 | |
Market cap | 12.75B | 9.8B | 11.09B | 11.83B | 12.61B | |
Enterprise value | 16.02B | 12.67B | 24.63B | 25.8B | 26.06B | |
P/E ratio | 7.34 | 12.82 | 3.62 | 32.5 | 14.33 | |
Price to sales ratio | 5.13 | 4.26 | 4.72 | 4.15 | 4.51 | |
POCF ratio | 25.75 | 20.98 | 20.5 | -123.22 | 16.55 | |
PFCF ratio | 34.36 | 29.86 | 27.87 | -45.5 | 20.44 | |
P/B Ratio | 2.61 | 1.98 | 1.97 | 2.09 | 2.24 | |
PTB ratio | 2.61 | 1.98 | 1.97 | 2.09 | 2.24 | |
EV to sales | 6.44 | 5.5 | 10.49 | 9.04 | 9.32 | |
Enterprise value over EBITDA | 28.3 | 27.6 | 253.9 | 86.3 | 66.14 | |
EV to operating cash flow | 32.36 | 27.12 | 45.52 | -268.78 | 34.2 | |
EV to free cash flow | 43.17 | 38.62 | 61.88 | -99.24 | 42.23 | |
Earnings yield | 0.03 | 0.02 | 0.07 | 0.01 | 0.02 | |
Free cash flow yield | 0.03 | 0.03 | 0.04 | -0.02 | 0.05 | |
Debt to equity | 0.83 | 2.53 | 2.67 | 2.67 | 2.62 | |
Debt to assets | 0.32 | 0.59 | 0.57 | 0.58 | 0.57 | |
Net debt to EBITDA | 5.77 | 6.25 | 139.54 | 46.74 | 34.13 | |
Current ratio | 1.72 | 4.73 | 1.63 | 1.67 | 1.59 | |
Interest coverage | 10.06 | 2.92 | 0.33 | 1.38 | 1.84 | |
Income quality | 1.14 | 2.42 | 0.7 | -1.03 | 3.45 | |
Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Payout ratio | 0.17 | 0.38 | 0.1 | 0.84 | 0.35 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | |
Intangibles to total assets | 0.16 | 0.09 | 0.43 | 0.43 | 0.43 | |
Capex to operating cash flow | -0.25 | -0.3 | -0.26 | 1.71 | -0.19 | |
Capex to revenue | -0.05 | -0.06 | -0.06 | -0.06 | -0.05 | |
Capex to depreciation | -1.16 | -1.32 | -0.89 | -0.92 | -0.8 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0 | 0.01 | |
Graham number | 63.69 | 42.54 | 90.9 | 31.34 | 48.45 | |
ROIC | 0.04 | 0.02 | -0.03 | 0.01 | 0.02 | |
Return on tangible assets | 0.04 | 0.01 | 0.05 | 0.01 | 0.02 | |
Graham Net | -41.25 | -39.67 | -144.83 | -144.37 | -142.66 | |
Working capital | 1.86B | 10.4B | 2.54B | 2.6B | 2.33B | |
Tangible asset value | 3.2B | 3.36B | -5.14B | -5.1B | -4.98B | |
Net current asset value | -3.03B | -2.85B | -13.56B | -13.51B | -13.31B | |
Invested capital | 0.83 | 2.53 | 2.67 | 2.67 | 2.62 | |
Average receivables | 1.87B | 1.72B | 1.83B | 2.18B | 2.14B | |
Average payables | 1.21B | 1.19B | 1.32B | 1.48B | 1.34B | |
Average inventory | 1.63B | 1.72B | 2.27B | 2.78B | 2.63B | |
Days sales outstanding | 66.14 | 63.05 | 78.73 | 72.97 | 63.21 | |
Days payables outstanding | 63.17 | 57.85 | 69.56 | 58.53 | 53.04 | |
Days of inventory on hand | 86.56 | 88.36 | 128.68 | 111.35 | 107.28 | |
Receivables turnover | 1.36 | 1.43 | 1.14 | 1.23 | 1.42 | |
Payables turnover | 1.42 | 1.56 | 1.29 | 1.54 | 1.7 | |
Inventory turnover | 1.04 | 1.02 | 0.7 | 0.81 | 0.84 | |
ROE | 0.09 | 0.04 | 0.14 | 0.02 | 0.04 | |
Capex per share | -1.14 | -1.28 | -1.32 | -1.51 | -1.33 |
CE Frequently Asked Questions
What is Celanese Corporation stock symbol ?
Celanese Corporation is a US stock , located in Irving of Tx and trading under the symbol CE
Is Celanese Corporation buy or a sell ?
19 stock analysts have 19 predictions with a medium analyst target price of $160.05. The lowest prediction is $111 and the highest is $206
What is CE stock prediction ?
With a median analyst target price of $147, 2 stock analysts have made 2 forecasts in last 90 days. $145 is the lowest and $149 is the greatest projection.
What is Celanese Corporation stock quote today ?
Celanese Corporation stock price is $122.01 today.
Is Celanese Corporation stock public?
Yes, Celanese Corporation is a publicly traded company.